With another calendar year just weeks away, forecasting experts are speculating on what the pharmaceutical pipeline will deliver in 2005. Lee Vermeulen, R.Ph., M.S., along with his colleagues at the University of Wisconsin Hospital and Clinics, believes the action in 2005 will be in biotech and that pharmacists should not ignore the agents currently being reviewed by the Food & Drug Administration.
